Japan’s Reimbursement Mechanism for Pharma Products — Stronger Than Before

Japan’s reimbursement mechanism for innovative pharmaceutical products

Japan is one of the countries that determines reimbursement pricing of pharmaceuticals the fastest. It updates its formulary four times a year, making its pharmaceutical market quite lucrative.

The country’s healthcare landscape and reimbursement pricing policies are changing rapidly. The reimbursement framework is being changed to a value-based one through the implementation of incremental cost-effectiveness ratios (ICERs) and cost‐effectiveness assessments (CEAs). In this insight paper, we cover the following:

  • Japan’s governing bodies and reimbursement mechanisms and policies

Key Takeaways

  • Reimbursement pricing assessment takes 60 days or a maximum of 90 days from market authorisation to patient access.

Originally published at https://www.acuitykp.com.

Author

Raghu Patale serves as Delivery Manager leading the Life Sciences Corporate Strategy Research and Consulting vertical. His responsibilities include thought leadership, setting up new client engagements, client management, and generating business insights. He has over 10 years of experience in conducting life science research as a competitive intelligence and strategy consultant. He has supported a wide spectrum of client engagements focusing on competitive intelligence, therapy area research, market opportunity assessments, M&A support and report writing in oncology and other therapy areas for US, EU5, and Asian geographies.

Prior to this, Raghu was a Group Manager, leading the Pharma Practice at Evalueserve. He holds a Master’s degree in Pharmaceutical Sciences from the National Institute of Pharmaceutical Education and Research (NIPER).

We write about financial industry trends, the impact of regulatory changes and opinions on industry inflection points. https://www.acuitykp.com/